Concentration of the Drug Ustekinumab in the Blood Four Weeks After Injection, Is Linked to How Well Moderate-To-Severe Psoriasis Responds to Treatment

British Journal of Dermatology - United Kingdom
doi 10.1111/bjd.18750
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Characterization of Insufficient Responders to Ustekinumab in Patients With Moderate-To-Severe Psoriasis in the US Corrona Psoriasis Registry

Journal of Dermatological Treatment
Dermatology
2020English

Ustekinumab in Real-Life Practice: Experience in 116 Patients With Moderate-To-Severe Psoriasis

Acta Medica Portuguesa
Medicine
2019English

Pss17 - Cost Per Responder Analysis of Brodalumab Compared With Ustekinumab in the Treatment of Moderate-To-Severe Plaque Psoriasis in Canada

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Transition to Ustekinumab in Patients With Moderate-To-Severe Psoriasis and Inadequate Response to Methotrexate: A Randomized Clinical Trial (TRANSIT)

British Journal of Dermatology
DermatologyMedicine
2014English

Costs of Treatment in Patients With Moderate to Severe Plaque Psoriasis

Archives of Dermatology
2004English

Effect of Prior Biologic Use on Cost-Effectiveness of Brodalumab vs. Ustekinumab for Treatment of Moderate-To-Severe Psoriasis in the United States

Dermatology and Therapy
Dermatology
2018English

A Network Meta-Analysis of Randomized, Controlled Trials of Ustekinumab and Adalimumab for Moderate-To-Severe Psoriasis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Oral Curcumin in the Treatment of Moderate to Severe Psoriasis Vulgaris: A Prospective Clinical Trial

Journal of the American Academy of Dermatology
Dermatology
2008English

How Inhibition Relates to Impulsivity After Moderate to Severe Traumatic Brain Injury

Journal of the International Neuropsychological Society
PsychiatryClinical PsychologyMental HealthNeurologyNeuroscience
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy